Schoenfeld SR, Castelino FV. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am. 2015;41: 237-248.
Silver KC, Silver RM. Management of systemic sclerosis-associated interstitial lung disease (SSc-ILD). Rheum Dis Clin North Am. 2015;41:439-457.
Stock CJW, Renzoni EA. Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature. Eur J Hum Genet. 2018;26:765-777.
Herzog EL, Mathur A, Tager AM, et al. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol. 2014;66:1967-1978.
Wells AU, Denton CP. Interstitial lung disease in connective tissue disease--mechanisms and management. Nat Rev Rheumatol. 2014;10:728-739.
Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006; 354:2655-2566.
Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008;133:455-460.
Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol. 2011;30:1393-1398.
Zamora AC, Wolters PJ, Collard HR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008;102:150-155.
Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962-3670.
Dheda K, Lalloo UG, Cassim B, et al. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol. 2004;23:306-309.
Berezne A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol. 2008;35:1064-72.
Sottile PD, Iturbe D, Katsumoto TR, et al. Outcomes in systemic sclerosis-related lung disease after lung transplantation. Transplantation. 2013;95:975-980.
Schachna L, Medsger TA Jr, Dauber JH, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2006;54:3954-3961.
Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74:1188-1194.
Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49:271-280.
Dellaripa PF. Interstitial lung disease in the connective tissue diseases; a paradigm shift in diagnosis and treatment. Clin Immunol. 2018;186:71-73.
Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387:2630-2640.
King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083-2092.
Seibold JR, Denton CP, Furst DE, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum. 2010;62:2101-2108.
Khanna D, Saggar R, Mayes MD, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011;63:3540-3546.
Prey S, Ezzedine K, Doussau A, et al. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol. 2012;167:1138-1144.
Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378:498-506.
van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311:2490-2498.
Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248-1254.
Allanore Y, Simms R, Distler O, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015;1:15002.
Coral-Alvarado PX, Méndez Patarroyo PA, Quintana López G. Systemic sclerosis. In Autoimmunity: From Bench to Bedside [Internet]. Bogota, Colombia: El Rosario University Press; 2013; https://www.ncbi.nlm.nih.gov/books/NBK459435/#systemicsclerosis.s1.
Bonroy C, Van Praet J, Smith V, et al. Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis. J Immunol Methods. 2012;379:53-60.
Günther J, Rademacher J, van Laar JM, et al. Functional autoantibodies in systemic sclerosis. Semin Immunopathol. 2015;37:529-542.
Vandecasteele E, De Pauw M, De Keyser F, et al. Six-minute walk test in systemic sclerosis: A systematic review and meta-analysis. Int J Cardiol. 2016;212:265-273.
LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573-1576.
https://www.hopkinsarthritis.org/physician-corner/rheumatology-rounds/round-30-selected-topics-in-systemic-sclerosis/
Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390:1685-1699.
Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43:2437-2444.
Steen VD, Medsger TA Jr. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66:940-944.
Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;11:1897-1905.
Khanna D, Nagaraja V, Tseng CH, et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther. 2015;17:372.
D'Angelo WA, Fries JF, Masi AT, et al. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46:428-440.
Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66:754-763.
Peytrignet S, Denton CP, Lund M, et al. Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology. 2018;57:370-381.
Tashkin DP, Volkmann ER, Tseng CH, et al. Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of Scleroderma Lung Study II. Chest. 2017;151:813-820.
Denton CP, Hughes M, Gak M, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology (Oxford). 2016;55:1906-1910.
Mango RL, Matteson EL, Crowson CS, et al. Assessing mortality models in systemic sclerosis-related interstitial lung disease. Lung. 2018. doi:10.1007/s00408-018-0126-6. [Epub ahead of print.]
Goh NS, Hoyles RK, Denton CP, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Rheumatol. 2017;69:1670-1678.
Hoffmann-Vold AM, Aaloken TM, Lund MB, et al. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol. 2015;67:2205-2212.
Flaherty KR, Mumford JA, Murray S, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:543-548.
Jeghal Y, Kim DS, Shim TS, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171:639-644.
Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003;168:531-537.
Khanna D, Mittoo S, Aggarwal R, et al. Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group. J Rheumatol. 2015;42:2168-2171.
Zappala CJ, Latsi PI, Nicholson AG, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:830-836
Kafaja SJ, Clements PJ, Wilhalme H, et al. Reliability and minimal clinically important differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II). Am J Resp Crit Care Med. 2017. doi: 10.1164/rccm.201709-1845OC. [Epub ahead of print]
Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol. 2014;66:1625-1635.
Assassi S, Sharif R, Lasky RE, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010;12:R166.
Liu X, Mayes MD, Pedroza C, et al. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res. 2013;65:1375-80.
Wu W, Jordan S, Becker M, et al. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. Ann Rheum Dis. 2018. doi: 10.1136/annrheumdis-2018-213201. [Epub ahead of print]
Zhang XJ, Bonner A, Hudson M, et al. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis. J Rheum. 2013;40:850-858.
Plastiras SC, Karadimitrakis SP, Ziakas PD, et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. 2006;55:598-602.
Caron M, Hoa S, Hudson M, et al. Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease. Eur Respir Rev. 2018;27. pii: 170102. doi: 10.1183/16000617.0102-2017.
Morgan C, Knight C, Lunt M, et al. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis. 2003; 62:146-150.
Khanna D, Tseng CH, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum. 2011;63:3078-3085.
Winstone TA, Assayag D, Wilcox PG, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. 2014;146:422-436.
Lopes AJ, Capone D, Mogami R, et al. Systemic sclerosis-associated interstitial pneumonia: evaluation of pulmonary function over a five-year period. J Bras Pneumol. 2011;37:144-151.
Lota HK, Renzoni EA. Circulating biomarkers of interstitial lung disease in systemic sclerosis. Int J Rheumatol. 2012;2012:121439.
Gupta L, Phatak S, Edavalath S. Biomarkers in scleroderma: current status. Indian J Rheumatol 2017;12(suppl S1):149-155.
Kowal-Bielecka O, Chwiesko-Monarowska S, Bernatowicz PL, et al. The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study. Rheumatology. 2017;56:844-852.
Benyamine A, Heim X, Resseguier N, et al. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease. Rheumatol Int. 2018;38:813-819.
Kuwana M, Shirai Y, Takeuchi T. Elevated serum Krebs von den Lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. J Rheumatol. 2016:43:1825-31.
Salazar GA, Kuwana M, Wu M, et al. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease. J Rheumatol. 2018 ; pii: jrheum.170518. doi:10.3899/jrheum.170518. [Epub ahead of print]
Hoffmann-Vold AM, Tennoe AH, Garen T, et al. High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis. Chest. 2016;150:299-306.
Tiev KP, Hua-Huy A, Gain M, et al. Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis. Eur Respir J. 2011;38:1355-1360.
Kodera M, Hasegawa M, Komura K, et al. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis. Arthritis Rheum. 2005;52:2889-2896.
Schupp J, Becker M, Gunther J, et al. Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis. Eur Respir J. 2014;43:1530-1532.
Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327-1339.
Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir and Crit Care Med. 2007;176:1026-1034.
Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655-2666.
Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708-719.
Elhai M, Dister O, Smith V, et al. Rituximab in systemic sclerosis: safety and efficacy data from the EUSTAR network. Presented at: EULAR: Annual European Congress of Rheumatology; June 13-16, 2018; Amsterdam. the Netherlands. Presentation OP0142.
Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378:35-47.
Pradere P, Turorache I, Magnusson, et al. Lung transplantation for scleroderma lung disease: an international, multicenter, observational cohort study. J Heart Lung Transplant. 2018;pii:S1053-2498(18)31388-3.
Shah RJ, Boin F. Lung transplantation in patients with systemic sclerosis. Curr Rheumatol Rep. 2017;19:23.
Kowal-Bielecka O, Landewé R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-628.
Suliman A, Al Harash A, Roberts WN, et al. Scleroderma-related interstitial lung disease. Respir Med Case Rep. 2017;22:109-112.
Allanore Y, Matucci-Cerinic M, Distler O. Treatment of systemic sclerosis: is there any hope for the future? RMD Open. 2016;2:e000260.
ClinicalTrials.gov. A study of the efficacy and safety of tocilizumab in participants with systemic sclerosis (SSc) (focuSSced). https://clinicaltrials.gov/ct2/show/NCT02453256. Accessed July 27, 2018.
ClinicalTrials.gov. A trial to compare nintedanib with placebo for patients with scleroderma related to lung fibrosis. https://clinicaltrials.gov/ct2/show/NCT02597933. Accessed July 27, 2018.
ClinicalTrials.gov. Scleroderma Lung Study III – combining pirfenidone with mycophenolate (SLSIII). https://clinicaltrials.gov/ct2/show/NCT03221257. Accessed July 27, 2018.
Khanna D, Jahreis A, Furst DE. Tocilizumab treatment of patients with systemic sclerosis: clinical data. J Scleroderma Relat Disord. 2017;2:S29-S35.
Xiao H, Zhang GF, Liao XP, et al. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease. Int J Rheum Dis. 2018;21:477-486.
Myllärniemi M, Kaarteenaho R. Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. Eur Clin Respir J. 2015;2:eCollection 2015.
Huang J, Beyer C, Palumbo-Zerr K, et al. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis. 2016;75:883-890.
Huang J, Maier C, Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76:1941-1948.
Desallais L, Avouac J, Fréchet M, et al. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res Ther. 2014;16:R157.
Khanna D, Albera C, Fischer A, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS Trial. J Rheumatol. 2016;43:1672-1679.
Distler O, Brown KK, Distler JHW, et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Clin Exp Rheumatol. 2017;35(suppl 106):75-81.
Khanna D, Denton CP, Lin CFJ, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate) Ann Rheum Dis. 2018;77:212-220.

CPD

Key Advances in the Treatment of Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)

Authors: Oliver Distler, MD; Jacob van Laar, MD, PhD; Vanessa Smith, MD, PhD; Anna-Maria Hoffmann-Vold, MD, PhD; Yannick Allanore, MD, PhD
CPD Released: 8/29/2018
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 8/29/2019

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US rheumatologists, pulmonologists, allergists, and clinical immunologists.

The treatment landscape for patients with SSc-ILD is evolving. Physicians have a critical need to understand the pathogenesis of SSc-ILD, the rationale and mode of action for the development of new treatments, and the efficacy and safety profiles of current and emerging therapies.

Upon completion of this activity, participants will have increased knowledge regarding the:

Complexity of SSc-ILD and evolving treatment landscape
Key data on current and emerging treatments for SSc-ILD
Expert opinions on the implications for clinical practice

Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Moderator

Oliver Distler, MD

Professor
Department of Rheumatology
University Hospital Zurich
Zurich, Switzerland

Disclosures

Disclosure: Oliver Distler, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; AnaMar; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; CSL Behring; GlaxoSmithKline; Inventiva; Italfarmaco; Medac; Merck & Co., Inc.; Mitsubishi Tanabe Pharma; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Target BioScience AG; UCB Pharma, Inc.
Received grants for clinical research from: Actelion Pharmaceuticals, Ltd; Bayer HealthCare; Mitsubishi Tanabe Parma; Roche Holdings AG

Faculty

Yannick Allanore, MD, PhD

Professor
Paris Descartes University
Cochin Hospital
Paris, France

Disclosures

Disclosure: Yannick Allanore, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Actelion Pharmaceuticals, Ltd; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Inventiva; Medac; Roche Holdings AG
Received grants for clinical research from: Roche Holdings AG; Inventiva

Anna -Maria Hoffmann-Vold, MD, PhD

Doctor
Oslo University Hospital
Oslo, Norway

Disclosures

Disclosure: Anna-Maria Hoffmann-Vold, MD, PhD, has disclosed no relevant financial relationships.

Vanessa Smith, MD, PhD

Professor
Ghent University
Ghent University Hospital
Ghent, Oost Vlaanderen, Belgium

Disclosures

Disclosure: Vanessa Smith, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Actelion Pharmaceuticals, Ltd; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.
Served as a speaker or a member of a speakers bureau for: Accord Healthcare; Actelion Pharmaceuticals, Ltd
Received grants for clinical research from: Actelion Pharmaceuticals, Ltd; Belgium Fund for Scientific Research in Rheumatic diseases; Fund of Scientific Research Flanders; Galapagos NV; Roche Holdings AG

Jacob van Laar, MD, PhD

Professor
Department of Rheumatology and Clinical Immunology
University Medical Center Utrecht
Utrecht, the Netherlands

Disclosures

Disclosure: Jacob van Laar, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly and Company; Merck Sharp & Dohme Corp.; Roche
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Merck Sharp & Dohme Corp.; Roche

Steering Committee

Luca Richeldi, MD, PhD (Chair)

Professor
Catholic University of the Sacred Heart
Agostino Gemelli University Hospital
Rome, Italy

Disclosures

Disclosure: Luca Richeldi, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Biogen Idec Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; InterMune, Inc.; Roche
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Cipla Ltd.; Roche; Vertex Pharmaceuticals Incorporated
Received grants for clinical research from: InterMune, Inc.

Members

Kevin Brown, MD

Professor
Vice Chair
National Jewish Health
Denver, Colorado, United States

Disclosures

Disclosure: Kevin Brown, MD, has disclosed the following relevant financial relationships:
Other: Aeolus Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; aTyr Pharma, Inc.; Biogen Idec Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; FibroGen, Inc.; Galapagos NV; Galecto Biotech; Genentech, Inc.; Gilead Sciences, Inc.; MedImmune Inc.; Novartis Pharmaceuticals Corporation; Patara Pharma, LLC; ProMetic Pharma Inc.; Roche; Third Pole Therapeutics

Vincent Cottin, MD, PhD

Professor
University of Lyon
Hôpital Louis Pradel
Lyon, France

Disclosures

Disclosure: Vincent Cottin, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; Galapagos NV; Gilead Sciences, Inc.; Promedior; Roche
Served as a speaker or a member of a speakers bureau for: Boehringer Ingelheim Pharmaceuticals, Inc.; Roche
Received grants for clinical research from: Boehringer Ingelheim Pharmaceuticals, Inc.; Roche

Christopher P. Denton, PhD, FRCP

Professor
Royal Free Hospital and University College London
London, United Kingdom

Disclosures

Disclosure: Christopher P. Denton, PhD, FRCP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Actelion Pharmaceuticals, Ltd; Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Corbus Pharmaceuticals Holdings, Inc.; Inventiva; Sanofi Aventis; Roche
Received grants for clinical research from: CSL Behring; GlaxoSmithKline; Inventiva; Roche

Marco Matucci-Cerenic, MD, PhD

Professor
University of Florence
Florence, Italy

Disclosures

Disclosure: Marco Matucci-Cerenic, MD, PhD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Actelion Pharmaceuticals, Ltd; Bristol-Myers Squibb Company; Pfizer Inc.
Received grants for clinical research from: Actelion Pharmaceuticals, Ltd

Madelon M.C. Vonk, MD, PhD

Assistant Professor
Radboud University Medical Centre
Nijmegen, the Netherlands

Disclosures

Disclosure: Madelon M.C. Vonk, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Actelion Pharmaceuticals, Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.
Received grants for clinical research from: Actelion Pharmaceuticals, Ltd; Therabel Pharma NV

Editor

Marinella Calle, PhD, CMPP

Scientific Director, WebMD Global, LLC

Disclosures

Disclosure: Marinella Calle, PhD, CMPP, has disclosed no relevant financial relationships.

Walid Amara, MD

Scientific Director, WebMD Global, LLC

Disclosures

Walid Amara,MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: BIOTRONIK; SERVIER
Served as a speaker or a member of a speakers bureau for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol-Myers Squibb Company; Livanova; MEDA; Medtronic, Inc.; MSD; Novartis; Pfizer Inc.; Physiomed; St. Jude;Servier

Content Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Key Advances in the Treatment of Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)

Authors: Oliver Distler, MD; Jacob van Laar, MD, PhD; Vanessa Smith, MD, PhD; Anna-Maria Hoffmann-Vold, MD, PhD; Yannick Allanore, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CPD Released: 8/29/2018

Valid for credit through: 8/29/2019

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

Section 1. Key Advances in the Treatment of Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)

Dr Distler introduces the program and presents the different segments
Oliver Distler, MD

Section 2. Pathogenesis of SSc-ILD and Rationale for New Treatment Options

Dr van Laar presents the mechanisms implicated in SSc-ILD pathogenesis and discusses current and investigational treatments
Jacob van Laar, MD, PhD

Section 3. Overview of SSc-ILD Burden and Unmet Needs

Dr Smith presents the unmet needs in SSc-ILD and prognostic factors of this pathology
Vanessa Smith, MD, PhD

Section 4. Identifying SSc-ILD Patients at Risk of Progression

Dr Hoffmann-Vold addresses SSc-ILD progression and the factors, particularly biomarkers, than can be used to identify a risk of progression
Anna-Maria Hoffmann-Vold, MD, PhD

Section 5. Established Treatment Options for SSc-ILD

Dr Allanore presents the key data for established treatment options of SSc-ILD
Yannick Allanore, MD, PhD

Section 6. Emerging and Investigational Treatments for SSc-ILD

Dr Distler presents the rationale and the key data for antifibrotic therapies in SSc-ILD
Oliver Distler, MD

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 9

CPD Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the European Medicines Agency for use in Europe and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

Oliver Distler, MD

Faculty

Yannick Allanore, MD, PhD

Anna -Maria Hoffmann-Vold, MD, PhD

Vanessa Smith, MD, PhD

Jacob van Laar, MD, PhD

Steering Committee

Luca Richeldi, MD, PhD (Chair)

Members

Kevin Brown, MD

Vincent Cottin, MD, PhD

Christopher P. Denton, PhD, FRCP

Marco Matucci-Cerenic, MD, PhD

Madelon M.C. Vonk, MD, PhD

Editor

Marinella Calle, PhD, CMPP

Walid Amara, MD

Content Reviewer

Nafeez Zawahir, MD

CPD

Key Advances in the Treatment of Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)

Target Audience and Goal Statement

Disclosures

Moderator

Oliver Distler, MD

Faculty

Yannick Allanore, MD, PhD

Anna -Maria Hoffmann-Vold, MD, PhD

Vanessa Smith, MD, PhD

Jacob van Laar, MD, PhD

Steering Committee

Luca Richeldi, MD, PhD (Chair)

Members

Kevin Brown, MD

Vincent Cottin, MD, PhD

Christopher P. Denton, PhD, FRCP

Marco Matucci-Cerenic, MD, PhD

Madelon M.C. Vonk, MD, PhD

Editor

Marinella Calle, PhD, CMPP

Walid Amara, MD

Content Reviewer

Nafeez Zawahir, MD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Key Advances in the Treatment of Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)

Contents of This CPD Activity

Educational Impact Challenge